ArticleJournal of neuro-oncology2010
Chordoid meningioma: a clinicopathologic study of 11 cases at a single institution.
Article in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Predictors of recurrence in the management of chordoid meningioma.Journal of neuro-oncology · 2016Pooled it
- Misdiagnosis of chordoma: A case report and a review of the literature.Oncology letters · 2025Article
- Lateral ventricle chordoid meningioma presenting with inflammatory syndrome in an adult male: A case report.Experimental and therapeutic medicine · 2023Article
- [Extra-axial chordoid meningioma: case report and literature review].The Pan African medical journal · 2023Review
- Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.Acta neuropathologica communications · 2022Article
- Clinical features, radiological findings, and prognostic factors for primary intracranial chordoid meningioma.Frontiers in neurology · 2022Article
- Chordoid meningioma: a clinico-pathological study of an uncommon variant of meningioma.Journal of neuro-oncology · 2018Article
- Uncommon Cranial Meningioma: Key Imaging Features on Conventional and Advanced Imaging.Clinical neuroradiology · 2017Review
- Spinal chordoid meningioma in a child: A case report and review of the literature.Oncology letters · 2015Article
- Chordoid Meningioma: Differentiating a Rare World Health Organization Grade II Tumor from Other Meningioma Histologic Subtypes Using MRI.AJNR. American journal of neuroradiology · 2015Article
- IgG4 overexpression is rare in meningiomas with a prominent inflammatory component: a review of 16 cases.Brain pathology (Zurich, Switzerland) · 2014Article
- Chordoid meningioma: a retrospective series of seven consecutive cases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Report of two cases of chordoid meningioma in patients with Castleman syndrome.Journal of neuro-oncology · 2011Article
- Pathological classification and molecular genetics of meningiomas.Journal of neuro-oncology · 2010Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordoid meningioma is an uncommon variant of meningioma, which histologically bears a great resemblance to chordoma and often follows an aggressive clinical course. We examine clinicopathologic features of 11 cases of this rare tumor to further elucidate its behavior. Thirteen specimens of chordoid meningioma belonging to 11 patients were obtained at a single institution from 1995 to 2009. Correlations of histologic parameters, immunohistochemical study, and clinical features were assessed. This series included six men and five women with a mean age of 60.8 years at first surgery. Aside from one patient (case 5) who died of disease immediately after the first operation, the mean postoperative follow-up period for the other 10 patients was 41.4 months. Two patients each had a local tumor recurrence. The mean time to recurrence was 10.4 years. No systemic manifestations of Castleman syndrome, such as iron-refractory hypochromic/microcytic anemia and dysgammaglobulinemia, were found. Six tumors (46%) were classified as benign (grade I) and seven tumors (54%) atypical (grade II), if based solely on histologic grading irrespective of chordoid or clear cell components in our cases. Lymphoplasmacytic infiltrate was moderate in one tumor (7%), mild in eight tumors (62%), and absent in four tumors (31%). The inflammatory cells were predominantly T cells (CD3+), with only scarce B cells (CD20+). There was a wide range of MIB-1 labeling indices (0.3-25.8%, mean 7.5%), which increased following tumor recurrence. Our study demonstrates that chordoid meningiomas are not always associated with Castleman's Syndrome, and that this histologic category can be seen in the elderly as opposed to only in younger age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.